Ceftolozane/tazobactam (C/T) is a novel β-lactam/β-lactamase inhibitor combination antibiotic approved by the US Food and Drug Administration for the treatment of complicated intra-abdominal and urinary tract infections due to Gram-negative bacteria, particularly extended-spectrum β-lactamase-producing Enterobacteriaceae and multidrug-resistant (MDR) Pseudomonas aeruginosa strains. Here we report a case of MDR P. aeruginosa skin and soft-tissue infection successfully treated with C/T. © 2017 International Society for Chemotherapy of Infection and Cancer
Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam
BASSETTI, MATTEO
2017-01-01
Abstract
Ceftolozane/tazobactam (C/T) is a novel β-lactam/β-lactamase inhibitor combination antibiotic approved by the US Food and Drug Administration for the treatment of complicated intra-abdominal and urinary tract infections due to Gram-negative bacteria, particularly extended-spectrum β-lactamase-producing Enterobacteriaceae and multidrug-resistant (MDR) Pseudomonas aeruginosa strains. Here we report a case of MDR P. aeruginosa skin and soft-tissue infection successfully treated with C/T. © 2017 International Society for Chemotherapy of Infection and CancerFile in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
ceftolozane-tazobactamMRD2017.pdf
non disponibili
Tipologia:
Versione Editoriale (PDF)
Licenza:
Non pubblico
Dimensione
157.19 kB
Formato
Adobe PDF
|
157.19 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
